Metoprolol
Metoprolol 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Cardiomyopathy, Hypertrophic Obstructive。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
13 项
已进入 III/IV 期
11 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Braveheart Bio, Inc.
- Norwegian University of Science and Technology
- Baker Heart and Diabetes Institute
- Western Sydney Local Health District
- Weill Medical College of Cornell University
- University of Michigan
- Bo Gregers Winkel
- Karolinska University Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
挪威、澳大利亚、美国、丹麦、瑞典、比利时、法国、Egypt、中国、Turkey (Türkiye)、Israel
正在招募患者的 Metoprolol 研究
Bariatric Surgery and Pharmacokinetics of Metoprolol
不适用招募中挪威NCT03519906Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
不适用招募中澳大利亚NCT04962711Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes
不适用招募中澳大利亚NCT07445334A Preliminary Study for INFORMED
IV 期招募中美国NCT05585125Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
IV 期招募中美国NCT07490067MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
IV 期招募中丹麦NCT07405229Optimization of Patient Preparation and Imaging Techniques for Cardiac CT
不适用招募中瑞典NCT06879769Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
IV 期招募中比利时NCT06864234Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction
III 期招募中法国NCT06518694Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse
III 期招募中挪威NCT05631730Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries
IV 期招募中EgyptNCT04914234UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
不适用招募中美国NCT07054489Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
III 期招募中中国NCT04980716Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
不适用招募中澳大利亚NCT04983823Aging, Beta Blockers, and Thermoregulatory Responses
IV 期招募中美国NCT06582680BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
III 期招募中美国NCT07755904Cardioprotection in AML
II 期招募中美国NCT04977180Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
不适用招募中美国NCT03504956Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
III 期招募中中国NCT06682169Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
不适用招募中Turkey (Türkiye)NCT07099677Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
IV 期招募中美国NCT06964464Early Beta Blocker Administration in STEMI Patients With SCAI B Status
不适用招募中IsraelNCT06967194A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
不适用招募中中国NCT07335900CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
III 期招募中美国NCT05931276
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。